Breast MRI should not be used for differential diagnosis between inflammatory breast cancer and acute mastitis AM prior to treatment. When mastitis symptoms persist after 10 to 15 days of well-managed medical treatment, MRI may be performed in addition to an ultrasound examination, a mammogram and to taking histological samples, in order to eliminate inflammatory breast cancer IBC. MRI and PET-CT seems to be useful for early detection of patients responding poorly to neoadjuvant chemotherapy so that the latter may be rapidly modified. The term mastitis is used when the breast is inflamed, for whatever reason, resulting in a breast that is red, hot and possibly painful.
Argus is an Assistant Professor of Radiology; and Dr. Mammography is the primary modality used for imaging the breast. However, it has known limitations. Dynamic contrast-enhanced breast magnetic resonance imaging MRI provides superior sensitivity to detect breast cancer and, when used in the appropriate clinical setting, it has become a useful adjunct to mammography. This, combined with the higher cost and limited availability of breast MRI vs. The American Cancer Society has outlined recommendations for the use of breast MRI for breast cancer screening and the American College of Radiology practice guidelines include 12 indications for the performance of breast MRI. The following clinical scenarios, for which breast MRI is indicated, will be reviewed: Preoperative evaluation of patients with newly diagnosed breast cancer, evaluation of breast cancer patients treated with neoadjuvant chemotherapy, evaluation of breast cancer patients with positive surgical margins following breast conservation therapy, evaluation of patients with metastatic axillary lymphadenopathy and an unknown primary malignancy, determination of silicone breast implant integrity, breast cancer screening in high risk women, and the use of breast MRI as a problem-solving tool for equivocal mammographic findings.
Breast MRI is the most sensitive method for detection of breast cancer. Depending on international health regulations, it is either applied for screening of women at high risk for developing breast cancer e. BRCA1 and BRCA2 carriers , as an additional diagnostic test in pretherapeutic breast cancer staging, monitoring of primary systemic therapies and for solving problematic diagnostic situations where direct biopsy is not possible. Editorial board note : this article is probably outdated, lacks structure and is in need of a major rewrite. If you are interested in refining it you are more than welcome.